Wolfe Research Downgrades Spyre Therapeutics to Peer Perform

Benzinga Newsdesk www.benzinga.com Negative 94.0%

Neg 94% Neu 0% Pos 0%

Wolfe Research analyst Andy Chen downgrades Spyre Therapeutics (NASDAQ:SYRE) from Outperform to Peer Perform.

Comments

No comments yet. Be the first!